-
On Jan. 5, 2009, the Food and Drug Administration (FDA) granted approval for generic stavudine capsules, USP, 30 mg and 40 mg, manufactured by Matrix Laboratories, Limited, Hyberdad, India. The application was originally reviewed under expedited review provisions for the President's Emergency Plan for AIDS Relief (PEPFAR) and granted tentative approval in April, 2007.
-
Mathematical models (a case reproduction number/stochastic model and a long-term epidemic dynamics/deterministic transmission model) were used to explore the effect of testing for all people 15 or older for HIV and initiating ARV therapy immediately after diagnosis.
-
One of President Barack Obama's first actions as president was to lift the ban on federal funds for international groups that perform abortions or provide information or counseling on abortion.
-
The combination of rapid HIV testing and brief prevention messages could be a model for use in jails which house a high-risk population.
-
HIV/AIDS researchers continue to find strong evidence that using rapid HIV testing in settings likely to capture high-risk populations is wise public health policy.
-
The scourge of HIV/AIDS, which continues to affect the African-American community disproportionately, highlights the importance of a comprehensive strategy to address the U.S. epidemic, federal public health officials recently stressed.
-
For correctional settings in many states the biggest obstacles to implementing an opt-out, rapid HIV testing program are state laws regarding HIV testing and counseling.
-
Investigators recently studied the scope of rapid HIV testing, finding surprisingly limited use in urban hospitals and HIV clinics in the United States.1,2,3
-
In this issue: FDA warning on topical anesthetics; antipsychotics increase sudden cardiac death; the step up vs step down debate; treating pain, fatigue, mood, and sleep in fibromyalgia; FDA Actions.
-
CDC investigators analyzed 15 years of surveillance data of culture-confirmed cases of tuberculosis from the 50 states and the District of Columbia, identifying 201,399 with isoniazid- and rifampin-susceptibility results.